Explore how groundbreaking cell and gene therapies (CAGTs) are revolutionizing previously untreatable diseases to improve the quality of life for patients. Join experts from IQVIA Biotech and IQVIA as they address the current state of CAGTs, regulatory strategies that move innovation forward and critical clinical development decisions.

Learning Objectives

• Gain insights into the dynamic regulatory landscape of CAGT trials and issues biotech sponsors should consider.
• Understand the challenges associated with CAGT clinical development, the advantages of early planning and the data-driven decisions crucial for the successful development of CAGTs.
• Discover how efficient operational models and expert cross-functional CAGT teams reduce complexity and accelerate clinical trials.

Speakers:

Erin Finot, MS, MBA
Vice President, Immuno-Oncology and CAGT

Diego Correa, MD, PhD, MSc
Vice President and Global Head, Cell and Gene Therapy Center of Excellence

Patrick Brady, PharmD
Global Head, Therapeutic Innovation and Regulatory Science